Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach
Abstract NAFLD is a leading comorbidity in HIV with an exaggerated course compared to the general population. Tesamorelin has been demonstrated to reduce liver fat and prevent fibrosis progression in HIV-associated NAFLD. We further showed that tesamorelin downregulated hepatic gene sets involved in...
Enregistré dans:
Auteurs principaux: | Lindsay T. Fourman, Takara L. Stanley, James M. Billingsley, Shannan J. Ho Sui, Meghan N. Feldpausch, Autumn Boutin, Isabel Zheng, Colin M. McClure, Kathleen E. Corey, Martin Torriani, David E. Kleiner, Colleen M. Hadigan, Raymond T. Chung, Steven K. Grinspoon |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/968ba8285b7d4c9dac1b0917f40794e7 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
par: Bedimo R
Publié: (2011) -
Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD
par: Lorena Pantano, et autres
Publié: (2021) -
NAFLD in the Elderly
par: Alqahtani SA, et autres
Publié: (2021) -
Targeting T Cell Subtypes for NAFLD and NAFLD-Related HCC Treatment: An Opinion
par: Chunye Zhang, et autres
Publié: (2021) -
NAFLD in type 1 diabetes: overrated or underappreciated?
par: Jonathan Mertens, et autres
Publié: (2021)